Ceritinib

Non-Small Cell Lung Cancer

PfizerSmall moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 59/ 100

Competitive context

1205 Active assets in the Non-Small Cell Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB
Onartuzumab Hoffmann-La Roche	Phase 3	BBB

View all 50 →

Same molecule, other indications

Ceritinib is also rated in:

pancreatic adenocarcinomaDormant

B

Indicative ·

57 / 100

Adenocarcinoma Lung Cancer; Squamous Cell Lung CarcinomaDormant

B

Indicative ·

56 / 100

BRAF wt AlleleDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.